Prostamax
Status
No approved product. No FDA-approved labeling exists. Not an FDA-approved medicine. Status in Russia and other countries was not verified for this entry.
What it is
A peptide preparation studied for prostate tissue markers.
What published research measured
A short peptide preparation from the Khavinson programme directed at prostate tissue, related conceptually to the prostate extract Prostatilen, which is a registered medicine in Russia for chronic prostatitis and benign prostatic hyperplasia. The extract carries what clinical literature exists; the synthetic short peptide sold under this name has substantially less, and it consists of single-institute preclinical and observational work without registered trials or independent replication. Prostate symptoms overlap with those of prostate cancer, which makes self-directed treatment of this particular organ system a poor context for an unevaluated compound.
Source
Khavinson programme publications; Prostatilen extract literature
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.